# NUCLEAR ANTIGEN MARKERS IN HUMAN BLOOD CELLS

> **NIH NIH R01** · VANDERBILT UNIVERSITY · 1989 · $115,038

## Abstract

The myeloid cell nuclear differentiation antigen (MNDA) is an m/r
55,000 protein that is specifically expressed in human myeloid
cells.  The significance of the presence or absence of the MNDA
in abnormalities of human myeloid cell growth and differentiation
will be established.  These results will be correlated with the
results from standard diagnostic tests and analysis of the ability
of abnormal hematopoietic cells to differentiate in vitro with or
without added inducers.  The nucleus is a location where control
over differentiation exists in the cell; therefore, the development
of markers of the nuclear status of hematopoietic cells could lead
to more reliable diagnosis in hematopathology.  A longterm
objective of the project is to contribute to the use of new
approaches to treating abnormalities of myeloid cell growth and
differentiation.  Monoclonal antibodies and immunoblotting
technology will be used to investigate physical characteristics and
the binding properties of the MNDA.  These antibodies will also be
used in microinjection experiments and in the localization of
MNDA at the ultrastructural level.  The gene(s) for the MNDA
will be cloned and the sequence information will be used to
establish homology to other proteins.  The MNDA is a low
abundance protein in expressing cells and the expression of
recombinant protein will be necessary for complete
characterization and functional analysis.  Additional information
on function will be obtained through the development of
appropriate gene constructs that will make it possible to express
the MNDA protein in cells that do not normally express the
MNDA and to inhibit the expression of the MNDA in expressing
cells.  Probes for the MNDA gene will be used to examine the
chromosomal location of the gene and elucidate the regulation of
its expression in leukemic cell lines and human hematopoietic
neoplasms.  The discovery of the MNDA provides a unique
opportunity to exploit the presence of a cellspecific nuclear
protein as a marker of human myeloid cells and as a tool to
investigate mechanisms that may be operating in the nucleus
during normal and abnormal myeloid cell differentiation.

## Key facts

- **NIH application ID:** 3174783
- **Project number:** 5R01CA037097-06
- **Recipient organization:** VANDERBILT UNIVERSITY
- **SAM.gov UEI:** GTNBNWXJ12D5
- **Principal Investigator:** ROBERT C BRIGGS
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 1989
- **Award amount:** $115,038
- **Award type:** 5
- **Project period:** 1984-04-01 → 1990-09-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/3174783

## Citation

> US National Institutes of Health, RePORTER application 3174783, NUCLEAR ANTIGEN MARKERS IN HUMAN BLOOD CELLS (5R01CA037097-06). Retrieved via MORVS 2026-10-25 from https://api.morvs.ai/grant/nih/3174783. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*